Xianzhi Zhao
Papers
3
Total Citations
13
H-Index
2
About
Xianzhi Zhao is a pioneering clinical researcher in the field of urologic oncology, with a focused expertise in neoadjuvant therapies for high-risk and oligometastatic prostate cancer. Dr. Zhao’s major contributions lie in developing and testing a novel “radiohormonal” approach—combining androgen deprivation therapy with precision radiotherapy prior to radical prostatectomy. This work challenges the traditional paradigm that metastatic disease is a contraindication for surgery. Through a phase I/II clinical trial, Zhao demonstrated the safety and feasibility of this multimodal strategy, reporting encouraging efficacy outcomes in oligometastatic patients. The impact of this foundational work is reflected in the growing citation of these early-phase studies, which have paved the way for the multicenter, randomized NEAR-TOP trial (2025). By authoring the protocol for this landmark study, Zhao is now leading efforts to rigorously compare radiohormonal therapy against the standard of care. Dr. Zhao’s research is notable for its translational ambition: aiming to delay castration resistance and prolong survival by integrating advanced robotic surgery with modern radiotherapy, offering new hope for patients with locally advanced and oligometastatic prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3